Genetic Associations With Toxicity-related Discontinuation of Aromatase Inhibitor Therapy for Breast Cancer

BACKGROUND: Up to 25% of patients discontinue adjuvant aromatase inhibitor (AI) therapy due to intolerable symptoms. Predictors of which patients will be unable to tolerate these medications have not been defined. We hypothesized that inherited variants in candidate genes are associated with treatme...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Henry, N. Lynn, Skaar, Todd C., Dantzer, Jessica, Li, Lang, Kidwell, Kelley, Gersch, Christina, Nguyen, Anne T., Rae, James M., Desta, Zeruesenay, Oesterreich, Steffi, Philips, Santosh, Carpenter, Janet S., Storniolo, Anna M., Stearns, Vered, Hayes, Daniel F., Flockhart, David A.
Format: Artigo
Idioma:Inglês
Publicat: 2013
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3646626/
https://ncbi.nlm.nih.gov/pubmed/23546553
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-013-2504-3
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars